The Long Run with Luke Timmerman Ep177: Kevin Parker on Finding Cancer Drug Targets
17 snips
Apr 14, 2025 Kevin Parker, CEO of Cartography Biosciences, reveals insights on discovering new cancer drug targets through innovative multi-omic tools. He shares his journey from a biologist in Pennsylvania to a leader in biotech, highlighting the personal drive behind his research. The discussion covers advancements in single-cell genomics, the challenges of drug discovery, and the potential impacts of targeted therapies on patient care. Parker emphasizes collaboration and strategic partnerships as key to navigating the complexities of cancer treatment innovation.
AI Snips
Chapters
Transcript
Episode notes
The CD19 Puzzle
- Kevin Parker's curiosity about CD19 CAR T-cell therapy's neurotoxicity sparked his research.
- He questioned why targeting B cells, specifically with CD19 therapies, caused neurological problems.
Cartography's Mission
- Cartography Biosciences aimed to find new cancer drug targets using single-cell genomics.
- Kevin Parker was motivated to translate scientific discoveries into patient therapies, leading him to start the company.
Focus on Antibodies
- Cartography Biosciences focuses on antibody therapeutics for cancer treatment.
- Antibodies effectively target cell surface antigens, making them suitable for precise drug delivery.